AU2023200828A1 — Methods and compositions for treating a Serpinc1-associated disorder
Assigned to Genzyme Corp · Expires 2023-03-16 · 3y expired
What this patent protects
OF THE INVENTION The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc Igene, and methods of using such iRNA, e.g., dsRNA, 5 compositions to inhibit expression of Serpinc1 and to treat subjects having a Serpincl assoc…
USPTO Abstract
OF THE INVENTION The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc Igene, and methods of using such iRNA, e.g., dsRNA, 5 compositions to inhibit expression of Serpinc1 and to treat subjects having a Serpincl associated disease, e.g., a bleeding disorder, such as a hemophilia.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.